190 related articles for article (PubMed ID: 30101858)
1. Phenotypic Screening Using Patient-Derived Induced Pluripotent Stem Cells Identified Pyr3 as a Candidate Compound for the Treatment of Infantile Hypertrophic Cardiomyopathy.
Sakai T; Naito AT; Kuramoto Y; Ito M; Okada K; Higo T; Nakagawa A; Shibamoto M; Yamaguchi T; Sumida T; Nomura S; Umezawa A; Miyagawa S; Sawa Y; Morita H; Lee JK; Shiojima I; Sakata Y; Komuro I
Int Heart J; 2018 Sep; 59(5):1096-1105. PubMed ID: 30101858
[TBL] [Abstract][Full Text] [Related]
2. Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients.
Wu H; Yang H; Rhee JW; Zhang JZ; Lam CK; Sallam K; Chang ACY; Ma N; Lee J; Zhang H; Blau HM; Bers DM; Wu JC
Eur Heart J; 2019 Dec; 40(45):3685-3695. PubMed ID: 31219556
[TBL] [Abstract][Full Text] [Related]
3. Endothelin-1 induces myofibrillar disarray and contractile vector variability in hypertrophic cardiomyopathy-induced pluripotent stem cell-derived cardiomyocytes.
Tanaka A; Yuasa S; Mearini G; Egashira T; Seki T; Kodaira M; Kusumoto D; Kuroda Y; Okata S; Suzuki T; Inohara T; Arimura T; Makino S; Kimura K; Kimura A; Furukawa T; Carrier L; Node K; Fukuda K
J Am Heart Assoc; 2014 Nov; 3(6):e001263. PubMed ID: 25389285
[TBL] [Abstract][Full Text] [Related]
4. Induced Pluripotent Stem Cell-Derived Cardiomyocytes from a Patient with MYL2-R58Q-Mediated Apical Hypertrophic Cardiomyopathy Show Hypertrophy, Myofibrillar Disarray, and Calcium Perturbations.
Zhou W; Bos JM; Ye D; Tester DJ; Hrstka S; Maleszewski JJ; Ommen SR; Nishimura RA; Schaff HV; Kim CS; Ackerman MJ
J Cardiovasc Transl Res; 2019 Oct; 12(5):394-403. PubMed ID: 30796699
[TBL] [Abstract][Full Text] [Related]
5. Enhanced myofilament calcium sensitivity aggravates abnormal calcium handling and diastolic dysfunction in patient-specific induced pluripotent stem cell-derived cardiomyocytes with MYH7 mutation.
Guo G; Wang L; Li X; Fu W; Cao J; Zhang J; Liu Y; Liu M; Wang M; Zhao G; Zhao X; Zhou Y; Niu S; Liu G; Zhang Y; Dong J; Tao H; Zhao X
Cell Calcium; 2024 Jan; 117():102822. PubMed ID: 38101154
[TBL] [Abstract][Full Text] [Related]
6. Inducible Pluripotent Stem Cell-Derived Cardiomyocytes Reveal Aberrant Extracellular Regulated Kinase 5 and Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Concomitantly Promote Hypertrophic Cardiomyopathy in RAF1-Associated Noonan Syndrome.
Jaffré F; Miller CL; Schänzer A; Evans T; Roberts AE; Hahn A; Kontaridis MI
Circulation; 2019 Jul; 140(3):207-224. PubMed ID: 31163979
[TBL] [Abstract][Full Text] [Related]
7. Applying Patient-Specific Induced Pluripotent Stem Cells to Create a Model of Hypertrophic Cardiomyopathy.
Dementyeva EV; Medvedev SP; Kovalenko VR; Vyatkin YV; Kretov EI; Slotvitsky MM; Shtokalo DN; Pokushalov EA; Zakian SM
Biochemistry (Mosc); 2019 Mar; 84(3):291-298. PubMed ID: 31221067
[TBL] [Abstract][Full Text] [Related]
8. Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells.
Han L; Li Y; Tchao J; Kaplan AD; Lin B; Li Y; Mich-Basso J; Lis A; Hassan N; London B; Bett GC; Tobita K; Rasmusson RL; Yang L
Cardiovasc Res; 2014 Nov; 104(2):258-69. PubMed ID: 25209314
[TBL] [Abstract][Full Text] [Related]
9. Modeling hypertrophic cardiomyopathy with human cardiomyocytes derived from induced pluripotent stem cells.
Li J; Feng X; Wei X
Stem Cell Res Ther; 2022 Jun; 13(1):232. PubMed ID: 35659761
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial Dysfunctions Contribute to Hypertrophic Cardiomyopathy in Patient iPSC-Derived Cardiomyocytes with MT-RNR2 Mutation.
Li S; Pan H; Tan C; Sun Y; Song Y; Zhang X; Yang W; Wang X; Li D; Dai Y; Ma Q; Xu C; Zhu X; Kang L; Fu Y; Xu X; Shu J; Zhou N; Han F; Qin D; Huang W; Liu Z; Yan Q
Stem Cell Reports; 2018 Mar; 10(3):808-821. PubMed ID: 29456182
[TBL] [Abstract][Full Text] [Related]
11. A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay.
Seeger T; Shrestha R; Lam CK; Chen C; McKeithan WL; Lau E; Wnorowski A; McMullen G; Greenhaw M; Lee J; Oikonomopoulos A; Lee S; Yang H; Mercola M; Wheeler M; Ashley EA; Yang F; Karakikes I; Wu JC
Circulation; 2019 Feb; 139(6):799-811. PubMed ID: 30586709
[TBL] [Abstract][Full Text] [Related]
12. Investigating the cardiac pathology of SCO2-mediated hypertrophic cardiomyopathy using patients induced pluripotent stem cell-derived cardiomyocytes.
Hallas T; Eisen B; Shemer Y; Ben Jehuda R; Mekies LN; Naor S; Schick R; Eliyahu S; Reiter I; Vlodavsky E; Katz YS; Õunap K; Lorber A; Rodenburg R; Mandel H; Gherghiceanu M; Binah O
J Cell Mol Med; 2018 Feb; 22(2):913-925. PubMed ID: 29193756
[TBL] [Abstract][Full Text] [Related]
13. Human-Induced Pluripotent Stem Cell-Derived Cardiomyocyte Model for
Kondo T; Higo S; Shiba M; Kohama Y; Kameda S; Tabata T; Inoue H; Okuno S; Ogawa S; Nakamura S; Takeda M; Ito E; Li J; Liu L; Kuramoto Y; Lee JK; Takashima S; Miyagawa S; Sawa Y; Hikoso S; Sakata Y
Circ Genom Precis Med; 2022 Oct; 15(5):e003522. PubMed ID: 35861968
[TBL] [Abstract][Full Text] [Related]
14.
Higgins EM; Bos JM; Dotzler SM; John Kim CS; Ackerman MJ
Circ Genom Precis Med; 2019 Nov; 12(11):e002648. PubMed ID: 31638832
[TBL] [Abstract][Full Text] [Related]
15. Divergent effects of adrenaline in human induced pluripotent stem cell-derived cardiomyocytes obtained from hypertrophic cardiomyopathy.
Prajapati C; Ojala M; Aalto-Setälä K
Dis Model Mech; 2018 Feb; 11(2):. PubMed ID: 29361520
[TBL] [Abstract][Full Text] [Related]
16. Severe DCM phenotype of patient harboring RBM20 mutation S635A can be modeled by patient-specific induced pluripotent stem cell-derived cardiomyocytes.
Streckfuss-Bömeke K; Tiburcy M; Fomin A; Luo X; Li W; Fischer C; Özcelik C; Perrot A; Sossalla S; Haas J; Vidal RO; Rebs S; Khadjeh S; Meder B; Bonn S; Linke WA; Zimmermann WH; Hasenfuss G; Guan K
J Mol Cell Cardiol; 2017 Dec; 113():9-21. PubMed ID: 28941705
[TBL] [Abstract][Full Text] [Related]
17. Hypertrophic cardiomyopathy in Noonan syndrome.
Nishikawa T; Ishiyama S; Shimojo T; Takeda K; Kasajima T; Momma K
Acta Paediatr Jpn; 1996 Feb; 38(1):91-8. PubMed ID: 8992870
[TBL] [Abstract][Full Text] [Related]
18. Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics.
Bhagwan JR; Mosqueira D; Chairez-Cantu K; Mannhardt I; Bodbin SE; Bakar M; Smith JGW; Denning C
J Mol Cell Cardiol; 2020 Aug; 145():43-53. PubMed ID: 32531470
[TBL] [Abstract][Full Text] [Related]
19. Hypertrophic cardiomyopathy dysfunction mimicked in human engineered heart tissue and improved by sodium-glucose cotransporter 2 inhibitors.
Wijnker PJM; Dinani R; van der Laan NC; Algül S; Knollmann BC; Verkerk AO; Remme CA; Zuurbier CJ; Kuster DWD; van der Velden J
Cardiovasc Res; 2024 Mar; 120(3):301-317. PubMed ID: 38240646
[TBL] [Abstract][Full Text] [Related]
20. Characterization of cardiac metabolism in iPSC-derived cardiomyocytes: lessons from maturation and disease modeling.
Vučković S; Dinani R; Nollet EE; Kuster DWD; Buikema JW; Houtkooper RH; Nabben M; van der Velden J; Goversen B
Stem Cell Res Ther; 2022 Jul; 13(1):332. PubMed ID: 35870954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
